Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager www.dendron.nihr.ac.uk/northeast Dementias and Neurodegenerative.

Similar presentations


Presentation on theme: "Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager www.dendron.nihr.ac.uk/northeast Dementias and Neurodegenerative."— Presentation transcript:

1 Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager www.dendron.nihr.ac.uk/northeast Dementias and Neurodegenerative Diseases Research Network

2 www.dendron.org.uk Team members also in Tees, Esk and Wear Valley NHS Trust and County Durham and Darlington NHS Trust Based at St Nicholas Hospital and Institute for Ageing and Health in Newcastle Dementias and Neurodegenerative Diseases Research Network

3 Where we fit in… Commissions and funds NHS and social care research Trains and develops researchers Supports facilities for research (e.g. Biomedical Research Units)  Cancer  Dementia and Neurodegenerative Diseases  Diabetes  Medicines for Children Mental Health  Stroke  Primary Care  Comprehensive

4 www.dendron.org.uk Research arm of NHS Facilitate studies for prevention, diagnosis, treatment Flexible Experienced Trained research support Dementias and Neurodegenerative Diseases Research Network

5

6 Range of studies in dementia – Imaging Studies Other interventional studies, costs of dementia and information use SUSPECTED-AD CATFieLD PRoVIDe Give and Take Clinical Trial of an Investigational Medicinal Product (CTIMPs) Observational, Investigative and Neuropsychiatric Studies DEMO-POD Newcastle Cognitive Fluctuation Scale DOMINO HTA-SADD MAIN-AD Scarlet Road Servier Dementias and Neurodegenerative Diseases Research Network

7 www.dendron.org.uk HTA-SADD Depression in dementia Which antidepressants effective? Testing mirtazapine and sertraline Double-blind placebo controlled trial, clinical and cost effectiveness Sponsored by the Alzheimer’s Society Recently reported – No benefit better than placebo

8 www.dendron.org.uk Blinded Placebo controlled trial Memantine vs Donepezil vs Both vs Placebo Severe Alzheimer’s Disease Follow up for 12 months

9 Direction of improvement 0 1 2 3 4 5 6 7 8 9 10 11 sMMSE 06183052 Visit Week placebo memantine donepezil donepezil and memantine Direction of improvement 22 24 26 28 30 32 34 36 38 40 42 BADLS 06183052 Visit Week Published NEJM 8 th March 2012

10 Testing an oral histamine H3 inverse agonist Presynaptic H3 receptors inhibit transmitter release - the inverse agonist should remove the inhibition and promote transmitter release Inclusion: Moderate Alzheimer’s, MMSE 12-20, stable on 10mg donepezil Servier Study DeNDRoN 076 Patient group - Alzheimer’s disease PI – Dr Andrew Byrne Recruiting across the North East NTW, TEWV, Gateshead, and Northumbria Trusts

11 Patient group – MCI (Prodromal Alzheimer’s) PI – Dr Bob Barber Recruiting across the North East NTW, TEWV, Gateshead, and Northumbria Trusts SCARLET ROAD STUDY DeNDRoN 055  Subcutaneous gantenerumab (monoclonal antibody) removes amyloid  2 year study in MCI – reduce risk of converting to dementia? Inclusion: MMSE >24, age 50-85

12 PROVIDE - Prevalence of Visual Impairment in People with Dementia 100 community dwelling 100 care home residents recruit, consent, MMSE referred to optometrists assess visual impairment how visual problems are managed recommend interventions to improve eye care Patient group – any dementia, mild, moderate or severe Research sites – TEWV, NTW, and Northumbria PIs – Helen Robinson, Bob Barber, and Julian Hughes recruiting across the North East

13 www.dendron.org.uk Brains for Dementia Research Brain tissue stored in the Newcastle Brain Tissue Resource Brains for Dementia Research (BDR) For anyone over 65 with a diagnosis of dementia, or controls Annual visit, collect clinical data

14 www.dendron.org.uk DeNDRoN Patient List  Patients use the Patient List to keep informed about studies  DeNDRoN uses the Patient List to recruit quickly to studies  Clinicians use the Patient List to give patients research opportunities

15 Patient List Disease Groups Alzheimer’s disease Parkinson’s disease Dementia with Lewy bodies Parkinson’s disease dementia Fronto-Temporal dementia Vascular dementia Mixed Vascular and Alzheimer’s dementia Progressive supranuclear palsy Mild Cognitive Impairment AD PD DLB PDD FTD VaD VaD/AD PSP MCI Over 550 patients – half of dementia patients have joined a study

16 www.dendron.org.uk Clinician and Researcher Involvement Refer to the Patient List Refer to the Patient List Refer to an existing study Refer to an existing study Register interest in a study recruiting elsewhere Register interest in a study recruiting elsewhere Develop a research proposal Develop a research proposal

17 www.dendron.org.uk Public / Patient Involvement Panel The PPI Panel The PPI Panel brings together patients and carers affected by all the disease groups included for clinical research by DeNDRoN Can supply quick lay opinion on proposed studies

18 www.dendron.org.uk Thank you! Tel: 0191 2232740 www.dendron.org.uk


Download ppt "Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager www.dendron.nihr.ac.uk/northeast Dementias and Neurodegenerative."

Similar presentations


Ads by Google